Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology
The widespread use of GLP-1 RAs has raised concerns regarding their ophthalmic safety. This study contributes new evidence from real-world data, suggesting that semaglutide and lixisenatide are associated with significant risks of ocular AEs. Further experimental studies are warranted to elucidate the underlying mechanisms and confirm these associations.
Authors
- Zhiwei Luo (ORCID: https://orcid.org/0000-0002-7605-9768)
- Ho‐Cheol Kang (ORCID: https://orcid.org/0000-0002-0448-1345)
- Dong Wang (ORCID: https://orcid.org/0000-0001-5137-0771)
- Jingru Gong
- Cui-Ting Chen
- Zhijie Zhang (ORCID: https://orcid.org/0009-0004-5943-4257)
- Xiang Li (ORCID: https://orcid.org/0009-0005-6470-727X)
Institutions
- Xiamen University (CN)
- Fudan University (CN)
- Kunming Medical University (CN)
- Pudong Medical Center (CN)
- Shanghai Pudong Institute of Education Development (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-10-19
- DOI
- https://doi.org/10.1080/14740338.2024.2419989
- Citations
- 14
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.01